Press release
Compugen Reports First Quarter 2022 Results
Triple blockade of PVRIG/TIGIT/PD-1 may be required to optimize clinical responsesCOM701, a unique check point inhibitor, with potential to recruit additional
About this update from Compugen Ltd.
[{"type":"text","content":"Triple blockade of PVRIG/TIGIT/PD-1 may be required to optimize clinical responsesCOM701, a unique check point inhibitor, with potential to recruit additional T cells to the TMECOM902 has the potential to be a best-in-class anti-TIGIT antibodyOn track to deliver clinical data from the cohort expansion study of COM701/nivolumab in MSS CRC in Q4 2022Enrollment continues in the Phase 1 clinical studies for COM701 and COM902Cash balance of $107 million affirms focus on capital efficiency with bold execution on Compugen's DNAM-1 axis hypothesisHOLON, Israel, May 16, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today financial results for the first quarter ended March 31, 2022 and provided a corporate update on key events since the start of 2022.\n\"I am excited about the outlook of Compugen's immune checkpoint inhibitors based on their unique characteristics, encouraging preliminary clinical data and our differentiated clinical development strategy,\" said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. We are the first to evaluate the triple blockade of the DNAM-1 axis, targeting PVRIG, TIGIT and PD-1 in the clinic. Based on the totality of the data we have to date on the PVRIG pathway, we believe triple blockade of PVRIG/TIGIT/PD-1 may be required for optimizing clinical responses in both inflamed and less inflamed tumors where other checkpoint inhibitors have so far been unsuccessful. Our Phase 1 clinical data demonstrated durable disease control rates, consistent immune activation, and good tolerability. With COM902, we are the first company to present clinical data with an IgG4 anti-TIGIT antibody, with low Fc-effector function. Having over a decade of expertise in this space, we believe this is the optimal design for an anti-TIGIT antibody. COM902 achieved a disease control rate of 50%. Unlike some other anti-TIGIT antibodies, to date studies have shown that COM902 avoids depletion of the CD8+ T cells, crucial for efficacy and we believe the IgG4 backbone may come with additional safety benefits. We look forward to proving our DNAM-1 axis hypothesis through our robust differentiated clinical strategy with studies designed to maximize the potential of COM701.\"\nDr. Cohen-Dayag also commente...